Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1442.

https://doi.org/10.1182/blood-2019-123845

Published: 2019

Journal Articles

Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations

Lucas R. Massoth, MD, Yin P. Hung, MD, PhD, Judith A. Ferry, MD, Robert P. Hasserjian, MD, Abner Louissaint, Jr., MD PhD, Meagan Montesion, PhD, Ethan S. Sokol, PhD, Dean C. Pavlick, Nikunj Shah, Natalie Danziger, Jonathan Keith Killian, MD,PhD, Eric A. Severson, MD, PhD, MMSc, Daniel Duncan, MD, Julia A. Elvin, MD, PhD, Vincent A. Miller, MD, Jeffrey S. Ross, MD, Jo-Anne Vergilio, MD, Lawrence R. Zukerberg, MD, Erik A. Williams, MD

Blood (2019) 134 (Supplement_1): 2541.

https://doi.org/10.1182/blood-2019-123729

Published: 2019

Journal Articles

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2018-99-115031

Published: 2018

Journal Articles

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srdan Verstovsek, MD PhD, Robert P. Hasserjian, MD, Olga Pozdnyakova, MD PhD, Ivo Veletic, MD, Ruben A. Mesa, MD, Lynda Foltz, MD FRCPC, John Mascarenhas, MD, Ellen K. Ritchie, MD, Jeanne Palmer, MD, Richard T. Silver, MD, Marina Kremyanskaya, MD PhD, Bernt van den Blink, MD PhD, Renu Gupta, MD, Taghi Manshouri, PhD, C. Cameron Yin, MD PhD, Zeev E. Estrov, MD, Jason R. Gotlib, MDMS

Blood (2018) 132 (Supplement 1): 686.

https://doi.org/10.1182/blood-2018-99-115362

Published: 2018

Journal Articles

Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

Olga K Weinberg, MD, Robert P. Hasserjian, MD, Ezra Baraban, MD, Chi Young Ok, MD, Julia T Geyer, MD, John KSS Philip, MD, Jason H. Kurzer, MD PhD, Heesun J. Rogers, MD PhD, Valentina Nardi, MD, Richard M. Stone, MD, Jacqueline S. Garcia, Eric D. Hsi, MD, Adam Bagg, MD, Sa A. Wang, MD, Attilio Orazi, MD, Daniel A. Arber, MD

Blood (2018) 132 (Supplement 1): 1491.

https://doi.org/10.1182/blood-2018-99-115198

Published: 2018

Journal Articles

National Survey Demonstrates Practice Gaps in Cytogenetic and Molecular Testing in Acute Myeloid Leukemia

Jessica K. Altman, MD, Ellen Denzen, MS, AnneMarie W. Block, PhD, Robert P. Hasserjian, MD, Heidi Klepin, MD, Bruno C Medeiros, MD, Amanda Noe, Wendy E Scales, PhD, Martin S. Tallman, MD, Kathleen Wiley, RN MSN AOCNS, Linda J. Burns, MD

Blood (2017) 130 (Supplement 1): 5602.

https://doi.org/10.1182/blood.V130.Suppl_1.5602.5602

Published: 2017

Journal Articles

Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression

Blood (2016) 128 (22): 753.

https://doi.org/10.1182/blood.V128.22.753.753

Published: 2016

Journal Articles

Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS -Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109

Kira Gritsman, MD PhD, Robert P. Hasserjian, MD, Taneisha Sinclair, David M. Weinstock, MD, Britta Will, PhD, Ulrich Steidl, MD PhD, Karen K. Ballen, MD, Amir T. Fathi, MD, Amit Verma, MD, Dejan Juric, MD, Philip C. Amrein, MD

Blood (2016) 128 (22): 2749.

https://doi.org/10.1182/blood.V128.22.2749.2749

Published: 2016

Journal Articles

TP53 Immunostaining in Double-Hit and Double-Expressing High-Grade B-Cell Lymphoma

Kwadwo Asare Oduro, Jr., MD PhD, Alexandra E. Kovach, MD, Jeremy S. Abramson, MD, Robert P. Hasserjian, MD, Aliyah R Sohani, MD

Blood (2016) 128 (22): 1876.

https://doi.org/10.1182/blood.V128.22.1876.1876

Published: 2016

Journal Articles

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

Srdan Verstovsek, MD, Ruben A. Mesa, Lynda M Foltz, MD, Vikas Gupta, MD MRCP, MRCPath, John O. Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD, Robert P. Hasserjian, MD, Elizabeth Trehu, MD, Mohamed E Salama, MD, Hagop M Kantarjian, MD, Jason Gotlib, MD

Blood (2015) 126 (23): 56.

https://doi.org/10.1182/blood.V126.23.56.56

Published: 2015

Journal Articles

Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma

Abner Louissaint, Jr., MD PhD, Kristian T. Schafernak, MD MPH, Julia T. Geyer, MD, Alexandra E. Kovach, MD, Dita Gratzinger, MD PhD, Christine G. Roth, MD, Christian N. Paxton, PhD, Sunhee Kim, Chungdak Namgyal, Elizabeth A. Morgan, MD, Sarah T. South, PhD, Marian H. Harris, MD PhD, Ephraim P. Hochberg, MD, Robert P. Hasserjian, MD, Nancy L. Harris, MD, David M. Weinstock, MD

Blood (2015) 126 (23): 3925.

https://doi.org/10.1182/blood.V126.23.3925.3925

Published: 2015

Journal Articles

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD, Lynda M Foltz, MD, Vikas Gupta, MD FRCP, FRCPath, John O Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD PhD, Robert P Hasserjian, MD, Elizabeth Trehu, MD, Hagop M. Kantarjian, MD, Jason R. Gotlib, MD

Blood (2014) 124 (21): 713.

https://doi.org/10.1182/blood.V124.21.713.713

Published: 2014

Journal Articles

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Catriona HM Jamieson, MD, PhD, Robert P Hasserjian, MD, Jason Gotlib, MD, MS, Jorge E. Cortes, MD, Richard M. Stone, MD, Moshe Talpaz, MD, Jürgen Thiele, MD, PhD, Scott J Rodig, MD, PhD, Abhay Patki, PhD MBA, Kaida Wu, PhD, MD, Jingyang Wu, MSc, Olga Pozdnyakova, MD, PhD

Blood (2013) 122 (21): 2823.

https://doi.org/10.1182/blood.V122.21.2823.2823

Published: 2013

Journal Articles

Refractory Anemia With Excess Blasts In Transformation (Acute Myeloid Leukemia with 20-29% Blasts) in Older Adults is Less Aggressive Than Acute Myeloid Leukemia With ≥30% Blasts

Blood (2013) 122 (21): 1345.

https://doi.org/10.1182/blood.V122.21.1345.1345

Published: 2013

Journal Articles

Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study

Heesun J. Rogers, MD, PhD, James W. Vardiman, MD, John Anastasi, MD, Gordana Raca, MD, PhD, Natasha M Savage, MD, Athena M Cherry, Ph.D., Daniel Arber, MD, Erika Moore, MD, Jennifer JD Morrissette, PhD, Adam Bagg, MD, Yen-Chun Liu, MD, PHD, Susan Mathew, PhD, Attilio Orazi, MD, Pei Lin, MD, Sa A. Wang, MD, Carlos E. Bueso-Ramos, MD, PhD, Kathryn Foucar, MD, Robert P Hasserjian, MD, Eric D. Hsi, MD

Blood (2012) 120 (21): 3847.

https://doi.org/10.1182/blood.V120.21.3847.3847

Published: 2012

Journal Articles

Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.

Marc HGP Raaijmakers, MD, PhD, Siddhartha Mukherjee, M.D., Shangqin Guo, PhD, Tatsuya Kobayashi, PhD, Jesse Schoonmaker, Zinmar Aung, Benjamin L. Ebert, MD, DPhil, Fatima Al-Shahrour, Robert P Hasserjian, MD, Sonia Vallet, MD, Edward Scadden, Charles P Lin, David T. Scadden, MD

Blood (2009) 114 (22): 247.

https://doi.org/10.1182/blood.V114.22.247.247

Published: 2009

Journal Articles

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

Pankaj Gupta, MD, Ben L. Sanford, MS, Daohai Yu, PhD, Ravi Vij, MD, David D. Hurd, MD, Olatoyosi Odenike, MD, Clara D. Bloomfield, MD, Robert P. Hasserjian, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 2665.

https://doi.org/10.1182/blood.V108.11.2665.2665

Published: 2006

Journal Articles

Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.

Chad P. Soupir, MD, Jo-Anne Vergilio, MD, Paola Dal Cin, PhD, Alona Muzikansky, MS, Hagop M. Kantarjian, MD, Dan Jones, MD, PhD, Robert P. Hasserjian, MD

Blood (2005) 106 (11): 3290.

https://doi.org/10.1182/blood.V106.11.3290.3290

Published: 2005

NARROW

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

National Survey Demonstrates Practice Gaps in Cytogenetic and Molecular Testing in Acute Myeloid Leukemia

Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression

Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS -Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109

TP53 Immunostaining in Double-Hit and Double-Expressing High-Grade B-Cell Lymphoma

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Refractory Anemia With Excess Blasts In Transformation (Acute Myeloid Leukemia with 20-29% Blasts) in Older Adults is Less Aggressive Than Acute Myeloid Leukemia With ≥30% Blasts

Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study

Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only